FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 歌禮製藥有限公司 呈交日期： 2025年10月3日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 01672 | 說明 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | | 佔有關事件 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | | | 致：香港交易及結算所有限公司 公司名稱: 歌禮製藥有限公司 本月底法定/註冊股本總額： USD 700,000 呈交日期: 2025年10月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01672 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 7,000,000,000 | USD | | 0.0001 | USD | | 700,000 | | 增加 / 減少 (-) | | | 0 | | | | USD | | 0 | | 本月底結存 | | | 7,000,000,000 | USD | | 0.0001 | USD | | 700,000 | FF ...

Group 1 - The article reports on share buybacks conducted by various companies on October 2, 2025, with Tencent Holdings leading in both the number of shares repurchased and the total amount spent [1] - Tencent Holdings repurchased 812,000 shares for a total of 550 million, representing 0.725% of its total share capital for the year [2] - Other notable companies involved in the buyback include Hang Seng Bank, which repurchased 200,000 shares for 23.94 million, and Cloud Factory, which repurchased 2 million shares for 9.59 million [2] Group 2 - The total number of shares repurchased by Tencent Holdings year-to-date is 66.625 million [2] - Hang Seng Bank's cumulative repurchase for the year stands at 8.73 million shares [2] - Cloud Factory's cumulative repurchase for the year is 6.109 million shares, indicating a significant buyback activity [2]

智通财经APP讯，歌礼制药-B(01672)发布公告，于2025年10月2日斥资66.61万港元回购6万股股份。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 歌禮製藥有限公司 呈交日期： 2025年10月2日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 01672 | 說明 | | | | | | | A. 已發行股份或庫存股份變動 | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | 事件 | | | 佔有關事件前的現有已發 | | 每股發行/出售價 (註4) | 已發行股份總數 | ...

Group 1 - Pharmaceutical stocks are experiencing a strong rally, with notable increases in share prices for companies such as Clover Biopharmaceuticals (up 20.26%), Genscript Biotech (up 15.05%), and others [1] - On September 26, former President Trump announced a 100% tariff on any brand or patented pharmaceutical products starting October 1, 2025, unless companies establish manufacturing facilities in the U.S. [1] - Southwest Securities predicts uncertainty regarding the implementation of this executive order, suggesting that Chinese innovative drug companies heavily reliant on the U.S. market may face short-term pressure [1] - China’s innovative drug companies that engage in business development (BD) overseas are expected to be less affected, particularly those involved in license-out agreements, which are essentially intellectual property transactions [1] - China Post Securities believes the actual impact of the tariffs will be minimal, viewing the current price drop as a good opportunity to increase holdings in innovative drugs [1] Group 2 - From the perspective of catalysts in the innovative drug sector, October will see significant industry conferences such as ESMO (October 17-21), followed by ASH and the San Antonio Breast Cancer Symposium in December [2] - There has been ongoing progress in outbound licensing transactions this year, with several significant deals already completed, indicating potential opportunities for high-quality domestic innovative drugs to enter international markets [2] - The fourth quarter is expected to bring domestic policy implementations, including adjustments to the medical insurance catalog [2]

Core Viewpoint - The company, Gilead Sciences (1672.HK), announced a share buyback plan, which has led to a nearly 13% increase in its stock price, reaching HKD 11.25. The buyback is intended to enhance shareholder value and reflects the company's confidence in its long-term business prospects [1]. Financial Position - The company stated that its current financial condition is stable, allowing it to allocate up to HKD 300 million for the share buyback [1]. - The buyback authorization permits the company to repurchase up to 96.2846 million shares, which is equivalent to 10% of the total issued shares [1]. Strategic Intent - The board believes that the proposed share buyback will increase the value of the shares and improve returns for shareholders [1]. - The decision to repurchase shares demonstrates the company's confidence in its growth potential and long-term business outlook, which is expected to ultimately benefit the company and its shareholders [1]. - The company will ensure that the buyback does not significantly impact its operating capital [1].

Core Viewpoint - The company, Gilead Sciences (1672.HK), announced a share buyback plan, which has led to a nearly 13% increase in its stock price, reflecting confidence in its long-term business prospects and growth potential [1] Group 1: Share Buyback Announcement - The company plans to utilize up to 300 million HKD from its internal financial resources for the proposed share buyback [1] - The buyback authorization allows the company to repurchase up to 96.2846 million shares, representing 10% of the total issued shares [1] - The board believes that the share buyback will enhance shareholder value and returns [1] Group 2: Financial Health and Confidence - The company stated that its current financial condition is stable [1] - The proposed buyback reflects the company's confidence in its long-term business outlook and growth potential [1] - The company will ensure that the buyback does not significantly adversely affect its operating capital [1]

消息面上，歌礼制药公布，其拟根据公司股东于今年5月22日举行的公司股东周年大会上授予董事会购 回公司股份的一般授权行使其权力，在合适时间于公开市场上购回股份。根据购回授权，公司获准购回 最多9628.46万股股份，相当于股东周年大会日期已发行股份(不包括库存股份)总数的10%。 歌礼制药-B(01672)涨超10%，截至发稿，涨10.23%，报10.99港元，成交额4277.41万港元。 于2025年9月29日，董事会已决定行使购回授权，并根据市况不时于公开市场购回股份，以使用最多3亿 港元的资金(拨付自公司内部财务资源)进行建议股份购回。董事会相信，建议股份购回反映公司对自身 的长远业务前景及公司的增长潜力充满信心，且最终将可惠及公司，并符合公司及公司股东整体的最佳 利益。 ...

于2025年9月29日，董事会已决定行使购回授权，并根据市况不时于公开市场购回股份，以使用最多3亿 港元的资金(拨付自公司内部财务资源)进行建议股份购回。董事会相信，建议股份购回反映公司对自身 的长远业务前景及公司的增长潜力充满信心，且最终将可惠及公司，并符合公司及公司股东整体的最佳 利益。 消息面上，歌礼制药公布，其拟根据公司股东于今年5月22日举行的公司股东周年大会上授予董事会购 回公司股份的一般授权行使其权力，在合适时间于公开市场上购回股份。根据购回授权，公司获准购回 最多9628.46万股股份，相当于股东周年大会日期已发行股份(不包括库存股份)总数的10%。 智通财经APP获悉，歌礼制药-B(01672)涨超10%，截至发稿，涨10.23%，报10.99港元，成交额4277.41 万港元。 ...